Twenty-eight patients with suspected or known steno-occlusive disease of the carotid ( n = 16 ) , renal ( n = 5 ) or peripheral arteries ( n = 7 ) were randomised to receive either 0.1 mmol/kg gadobenate dimeglumine or 0.2 mmol/kg gadopentetate dimeglumine for a first CE-MRA procedure .